Published in Calcif Tissue Int on June 24, 2016
Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget (2017) 0.75
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 24.00
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 14.25
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
The amazing osteocyte. J Bone Miner Res (2011) 5.32
WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med (2013) 4.52
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest (2011) 4.43
Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell (2007) 4.31
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med (2005) 4.17
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature (2009) 4.14
Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell (2007) 3.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell (2014) 3.13
Arteriolar niches maintain haematopoietic stem cell quiescence. Nature (2013) 3.07
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Identification and specification of the mouse skeletal stem cell. Cell (2015) 2.59
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr (2009) 2.26
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res (2012) 1.75
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood (2007) 1.75
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res (2009) 1.72
Marrow fat and bone--new perspectives. J Clin Endocrinol Metab (2013) 1.60
Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood (2014) 1.60
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Ann N Y Acad Sci (2014) 1.54
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A (2010) 1.44
Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res (2003) 1.41
Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab (2014) 1.37
Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS One (2013) 1.34
The neural crest is a source of mesenchymal stem cells with specialized hematopoietic stem cell niche function. Elife (2014) 1.28
Role of decorin in the antimyeloma effects of osteoblasts. Blood (2008) 1.19
Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res (2010) 1.18
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood (2005) 1.13
Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone (1991) 1.13
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One (2010) 1.11
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res (2013) 1.11
Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res (2011) 1.06
Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. Nat Commun (2015) 1.06
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma (2005) 1.03
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol (2004) 1.03
A High Fat Diet Increases Bone Marrow Adipose Tissue (MAT) But Does Not Alter Trabecular or Cortical Bone Mass in C57BL/6J Mice. J Cell Physiol (2015) 1.01
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia (2012) 1.00
Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia (2007) 0.97
SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep (2014) 0.97
A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood (2012) 0.97
Osteoporosis and obesity: Role of Wnt pathway in human and murine models. World J Orthop (2014) 0.96
Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs (2009) 0.96
Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT). PLoS One (2011) 0.95
Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun (2015) 0.95
Phenotypic and functional heterogeneity of human bone marrow- and amnion-derived MSC subsets. Ann N Y Acad Sci (2012) 0.94
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone (2013) 0.94
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol (2014) 0.93
Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther (2016) 0.93
PKA/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells. Leukemia (2014) 0.93
Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS One (2015) 0.93
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood (2014) 0.93
Relationship between MRI-measured bone marrow adipose tissue and hip and spine bone mineral density in African-American and Caucasian participants: the CARDIA study. J Clin Endocrinol Metab (2012) 0.92
Body mass index and physical activity at different ages and risk of multiple myeloma in the NIH-AARP diet and health study. Am J Epidemiol (2013) 0.92
Bone marrow fat accumulation accelerated by high fat diet is suppressed by exercise. Bone (2014) 0.92
Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood (2014) 0.91
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Res (2016) 0.91
Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol (2015) 0.90
RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Res (2012) 0.90
Osteoblast recruitment routes in human cancellous bone remodeling. Am J Pathol (2014) 0.88
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol (2008) 0.86
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One (2013) 0.86
De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue. FASEB J (2015) 0.85
Bone and fat: a relationship of different shades. Arch Biochem Biophys (2014) 0.85
Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Res (2016) 0.85
The Relationship of Fat Distribution and Insulin Resistance with Lumbar Spine Bone Mass in Women. PLoS One (2015) 0.85
unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res (2014) 0.84
Obesity-driven disruption of haematopoiesis and the bone marrow niche. Nat Rev Endocrinol (2014) 0.84
Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget (2015) 0.84
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone (2015) 0.83
Exercise Regulation of Marrow Fat in the Setting of PPARγ Agonist Treatment in Female C57BL/6 Mice. Endocrinology (2015) 0.82
Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. Exp Hematol (2014) 0.82
Dose-dependent effect of estrogen suppresses the osteo-adipogenic transdifferentiation of osteoblasts via canonical Wnt signaling pathway. PLoS One (2014) 0.81
Bone marrow-derived mesenchymal cell differentiation toward myogenic lineages: facts and perspectives. Biomed Res Int (2014) 0.81
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res (2015) 0.81
Bone anabolic agents for the treatment of multiple myeloma. Cancer Microenviron (2011) 0.81
Heterogeneity of the bone marrow niche. Curr Opin Hematol (2016) 0.80
Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma. J Cancer Res Clin Oncol (2015) 0.80
Histomorphometric evaluation of the effects of ovariectomy on bone turnover in rat caudal vertebrae. Calcif Tissue Int (1999) 0.80
Diet and gene interactions influence the skeletal response to polyunsaturated fatty acids. Bone (2014) 0.80
Negative Skeletal Effects of Locally Produced Adiponectin. PLoS One (2015) 0.79
Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Curr Oncol (2013) 0.79
Osteogenic inhibition in multiple myeloma. Cell J (2013) 0.79
Comparison of the relationship between bone marrow adipose tissue and volumetric bone mineral density in children and adults. J Clin Densitom (2013) 0.79
The Skeletal Cell-Derived Molecule Sclerostin Drives Bone Marrow Adipogenesis. J Cell Physiol (2017) 0.75
Cover Image, Volume 232, Number 12, December 2017. J Cell Physiol (2017) 0.75
A Perspective on Malignancy in the Marrow. J Cell Physiol (2017) 0.75
A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. Am J Hematol (2017) 0.75